Dessale et al., 2022 - Google Patents
Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosisDessale et al., 2022
View HTML- Document ID
- 2955484547279624380
- Author
- Dessale M
- Mengistu G
- Mengist H
- Publication year
- Publication venue
- International Journal of Nanomedicine
External Links
Snippet
Cancer remains the most devastating disease and the major cause of mortality worldwide. Although early diagnosis and treatment are the key approach in fighting against cancer, the available conventional diagnostic and therapeutic methods are not efficient. Besides …
- 201000011510 cancer 0 title abstract description 142
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
- A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
- A61K47/48769—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form
- A61K47/48853—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere
- A61K47/48861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the conjugate being characterized by a special physical or galenical form the form being a particulate, powder, adsorbate, bead, sphere the form being an inorganic particle, e.g. a ceramic particle, silica particle, ferrite, synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dessale et al. | Nanotechnology: a promising approach for cancer diagnosis, therapeutics and theragnosis | |
Wu et al. | Aptamers: active targeting ligands for cancer diagnosis and therapy | |
Pucci et al. | Innovative approaches for cancer treatment: Current perspectives and new challenges | |
Wang et al. | Chemically edited exosomes with dual ligand purified by microfluidic device for active targeted drug delivery to tumor cells | |
Tao et al. | Metal nanoclusters: novel probes for diagnostic and therapeutic applications | |
Katakowski et al. | Exosomes as tools to suppress primary brain tumor | |
Kievit et al. | Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs | |
Mokhtarzadeh et al. | Aptamers as smart ligands for nano-carriers targeting | |
Xiao et al. | Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities | |
Ye et al. | ZnO-based nanoplatforms for labeling and treatment of mouse tumors without detectable toxic side effects | |
Srivastava et al. | Exosomes as theranostics for lung cancer | |
Han et al. | Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy | |
Šamec et al. | Nanomedicine and immunotherapy: a step further towards precision medicine for glioblastoma | |
Araujo-Abad et al. | Biomedical application of small extracellular vesicles in cancer treatment | |
Liu et al. | MicroRNA-responsive cancer cell imaging and therapy with functionalized gold nanoprobe | |
Zhao et al. | Exosomes as smart nanoplatforms for diagnosis and therapy of cancer | |
Xu et al. | Emerging nanobiotechnology for precise theranostics of hepatocellular carcinoma | |
Davodabadi et al. | Aptamer‐functionalized quantum dots as theranostic nanotools against cancer and bacterial infections: a comprehensive overview of recent trends | |
Khademi et al. | Nanotechnology-based diagnostics and therapeutics in acute lymphoblastic leukemia: a systematic review of preclinical studies | |
Krishnan et al. | Handbook on nanobiomaterials for therapeutics and diagnostic applications | |
Walia et al. | Aptamer-programmed DNA nanodevices for advanced, targeted cancer theranostics | |
Deng et al. | Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer | |
Jia et al. | Synergetic tumor probes for facilitating therapeutic delivery by combined-functionalized peptide ligands | |
Deng et al. | Two-step assembling of near-infrared “off–on” fluorescent nanohybrids for synchronous tumor imaging and microrna modulation-based therapy | |
Chen et al. | Engineered exosomes as drug and RNA co-delivery system: new hope for enhanced therapeutics? |